TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01663857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2228820
Description: Administered Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2228820
Description: Administered Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2228820
Description: Administered Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Administered IV
Study: NCT04835883

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CS20AT04 (allogenic bone marrow derived mesenchymal stem cell)
Description: Two intravenous infusions of CS20AT04 (2.0×10\^6cell/kg), on 0 day and on 12 weeks The target population of this study is subjects in South Korea with a diagnosis of either lupus nephritis or lupus cytopenia.
Study: NCT02329782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Readiness Program
Description: The ARP consists of pre-treatment (including practice trials to determine readiness for and timing of ART initiation), early-treatment, and ongoing maintenance training (using a performance-based, dose regulation mechanism to tailor the amount and intensity) phases
Study: NCT00623298

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group IPT

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: 6 months-baseline
Study: NCT04047732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB105
Description: KB105, a replication-incompetent, non-integrating HSV-1 vector expressing human transglutaminase 1 (TGM1) formulated as a topical gel
Study: NCT00063336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: A computerized cognitive rehabilitation treatment with day-program activities

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-skills training
Description: A computerized cognitive rehabilitation treatment with day-program activities
Study: NCT01619098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigator
Description: In addition to usual care, the intervention adds the services of a community health worker, the Patient Navigator (PN), for study patients. The PN participates in bedside meetings, facilitates communication between the patient and the primary care team, conducts weekly outreach phone calls to further address patient needs, and makes reminder calls prior to all medical appointments to facilitate timely outpatient follow-up.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care includes provision of a Home Care Plan (HCP) to patients at discharge, and electronic transmission of HCP to PCP with telephone follow-up by primary care RN
Study: NCT06462742

Intervention type: PROCEDURE
Intervention: Microwave ablation (MWA) versus Liver Resection (LR)
Description: Microwave ablation (MWA) is one of the newer modality of thermal ablation and has proven its safety and efficacy in the management of the tumors amenable for ablation for primary and metastatic diseases.~Liver resection is a surgery to remove part of the liver to eradicate tumors.

Intervention type: PROCEDURE
Intervention: Microwave ablation (MWA) versus Liver Resection (LR)
Description: Microwave ablation (MWA) is one of the newer modality of thermal ablation and has proven its safety and efficacy in the management of the tumors amenable for ablation for primary and metastatic diseases.~Liver resection is a surgery to remove part of the liver to eradicate tumors.
Study: NCT02500719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computational Model - Real-time Support Vector Machine
Description: A support vector machine algorithm will be applied in real-time to fMRI data to identify distributed patterns of co-activated brain regions that specifically encode high emotional arousal (i.e,. high SCR) to the stress/trauma memory (note, this is equivalent to predictions of fitted Q-iteration in which the all actions are specified as zero, reward is equal to the support vector machine predicted arousal, and the discount factor of 0). The resulting idiosyncratic brain map would inform the neurofeedback phase in the next stage of fMRI data collection. This approach will first be piloted in the healthy participant group, then implemented in the PTSD participant group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computational Model - Real-time Support Vector Machine
Description: A support vector machine algorithm will be applied in real-time to fMRI data to identify distributed patterns of co-activated brain regions that specifically encode high emotional arousal (i.e,. high SCR) to the stress/trauma memory (note, this is equivalent to predictions of fitted Q-iteration in which the all actions are specified as zero, reward is equal to the support vector machine predicted arousal, and the discount factor of 0). The resulting idiosyncratic brain map would inform the neurofeedback phase in the next stage of fMRI data collection. This approach will first be piloted in the healthy participant group, then implemented in the PTSD participant group.
Study: NCT04522570

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser ablation
Description: Single session with Diode laser ablation system; one or two applicators will be used for treatments; one to three illuminations; fixed output power of 3 watts (W); pullback technique; delivered energy: 1200-1800 Joules (J) varying according to tumor volume; treatment under local anesthesia +- conscious or moderate sedation;

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoablation
Description: Single session with Argon-based cryoablation system; one 17 Gauge (G) V-probe applicator will be used for treatments; fixed gas delivery of 100%; treatment under local anesthesia +- conscious or moderate sedation;

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Single session with radiofrequency generator; one 17 Gauge (G) V-tip applicator with a 1 to 4cm active tip; moving-shot technique or multiple overlapping shot technique with 60 Watts (W) output power; treatment under local anesthesia +- conscious or moderate sedation;
Study: NCT03955809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0.5
Description: İntrarticular Ketamine 0.5 mg/kg + 0.9 Nacl Total Volume 20 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 1
Description: İntrarticular Ketamine 1 mg/kg + 0.9 NaCl Total Volume 20 ml

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: % 0.9 NaCl
Description: Intraarticular %0.9 NaCl
Study: NCT00634296

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle added by aerobic to aerobic alone
Description: Inspiratory muscle added by aerobic to aerobic alone
Study: NCT01015105

Intervention type: OTHER
Intervention: observation
Description: observation
Study: NCT01344759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of dexmedetomidine 1 mcg/kg will be administered over 10 minutes followed by a continuous infusion of dexmedetomidine at rate of 1 mcg/kg/h using a syringe pump.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of propofol 2 mg/kg will be administered over 2 minutes followed by a continuous infusion of propofol at rate of 100 mcg/kg/minute using a syringe pump.
Study: NCT01212146

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei IMPC 2.1 LMGP22043
Description: participants will complement their usual lifestyles and dietary intakes with probiotic artichokes, enriched with the probiotic strain Lactobacillus paracasei IMPC2.1 (LMGP22043). The product contains approximately 1.20 x 10\^8 CFU of live probiotic cells of Lactobacillus paracasei IMPC 2.1 LMGP22043 per gramme, which resulted in a daily dose of about 2 x 10\^10 CFU.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ordinary artichokes
Description: Probiotic artichokes will be tested against ordinary artichokes (probiotic free) of identical shape, texture, and appearance produced by the same manufacturer. Artichokes will be put in similar packages and there will be no way to distinguish between the two products.
Study: NCT02542137

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of small cell lung cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymalfasin
Description: Patients with metastatic lesions of small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
Study: NCT00591929

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Passive Motion
Description: at least 48 hours of continuous passive motion following ORIF of fractures around the knee
Study: NCT00565201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox and rehab
Description: Patients will BOTOX® (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and rehab
Description: Patients will receive placebo saline (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
Study: NCT01856998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprivan
Study: NCT00458861

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG9924
Description: Subcutaneous administration of BG9924 given every other week for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Subcutaneous administration of placebo given every other week for 12 weeks
Study: NCT03389880

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: A surgical procedure in which parts of the knee joint are replaced with artificial parts (prostheses)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: A surgical procedure in which parts of the knee joint are replaced with artificial parts (prostheses)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patellar denervation
Description: circumpatellar electrocautery with monopolar coagulation diathermy
Study: NCT00488137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 2 mg o.d.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: o.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 4 mg o.d.
Study: NCT02834078

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BGG

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03971916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM9161(HL161BKN)
Description: Subcutaneous injection; Single dose on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM9161(HL161BKN)
Description: Subcutaneous injection; Single dose on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM9161(HL161BKN)
Description: Subcutaneous injection; Single dose on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection; Single dose on Day 1
Study: NCT02512172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral CC-486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral CC-486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Study: NCT04542876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guduchi Ghan Vati
Description: Guduchi Ghan Vati was orally administered 2 tablets (1000 mg) twice daily for 2 weeks.
Study: NCT02032615

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Education plus Gudness Nutritional Bar

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education
Study: NCT04433923

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy with aluminum foil

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Phototherapy without aluminum foil
Study: NCT00545935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylenblue-Amodiaquine (MB-AQ)
Description: For 3 days twice daily 10 mg/kg MB accompanied by once daily 10 mg/kg AQ

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylenblue-Artesunate (MB-AS)
Description: 3 days once daily 4 mg/kg AS accompanied by twice daily 10 mg/kg MB given over 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate-Amodiaquine (AS-AQ)
Description: For 3 days once daily 10 mg/kg AQ accompanied by 4mg/kg AS.
Study: NCT03175315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment and education program for patients with diabetes who use flash glucose monitoring (FLASH)
Description: Treatment and education program based on the self-management theory of behavioral medicine. The program is delivered by certified and specially trained diabetes educators.
Study: NCT03324477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hypertonic saline 3%
Description: hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hypertonic saline 3%
Description: hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma
Study: NCT04290000

Intervention type: OTHER
Intervention: additional biological samples during CAR-T CELL treatment
Description: Blood samples (additional tubes) and marrow (quantity taken in addition from the same aspiration) will be collected in addition to those useful for the follow up of the patients (progress of their disease after treatment with CAR-T Cells) at specific points in his treatment journey.~The following samples will also be collected during Apheresis and at Car-T Cells reinjection :~* Apheresis sampling~* CAR-T Cells collected from bag rinsate~In case of invasion, a skin biopsy will be made, 2 days and 8 days after the beginning of the CAR T Cell Treatment, during the patient's hospitalization and during a consultation visit in case of therapeutic progression or failure.
Study: NCT01399385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR Imaging Techniques - 1
Description: Group 1 will consist of subjects with a 10-year total CHD risk \<10% (low)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR Imaging Techniques - 2
Description: Group 2 will consist of subjects with a 10-year total CHD risk 10-20% (intermediate)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR Imaging Techniques - 3
Description: Group 3 will consist of subjects with a 10-year total CHD risk \>20% (high)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR Imaging Techniques - 4
Description: Group 4 no known risk factors (control subjects)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
Study: NCT03624712

Intervention type: DIAGNOSTIC_TEST
Intervention: uterine neoplasms
Description: Analysis of circulating (CTC) and disseminating tumor cells (DTC), determination of Human Papilloma Virus (HPV), Douglas cytology, DNA analysis in blood, proteome analysis, sentinel lymph node detection
Study: NCT02827175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Study: NCT02016911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: semaglutide
Description: Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
Study: NCT03809234

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron 8mg with Saline & Tariquidar
Description: Each participant will receive two IV infusions of ondansetron, 24 hours apart. In the first and second sessions, respectively, placebo (D5W) or tariquidar (4mg/kg dose in D5W) 22 will be administered IV over 60 minutes. Ondansetron will be diluted in 50mL 0.9% normal saline, and tariquidar will be diluted in 250mL D5W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg with Saline & Tariquidar
Description: Each participant will receive two IV infusions of ondansetron, 24 hours apart. In the first and second sessions, respectively, placebo (D5W) or tariquidar (4mg/kg dose in D5W) 22 will be administered IV over 60 minutes. Ondansetron will be diluted in 50mL 0.9% normal saline, and tariquidar will be diluted in 250mL D5W.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron 16mg with Saline & Tariquidar
Description: Each participant will receive two IV infusions of ondansetron, 24 hours apart. In the first and second sessions, respectively, placebo (D5W) or tariquidar (4mg/kg dose in D5W) 22 will be administered IV over 60 minutes. Ondansetron will be diluted in 50mL 0.9% normal saline, and tariquidar will be diluted in 250mL D5W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 16mg with Saline & Tariquidar
Description: Each participant will receive two IV infusions of ondansetron, 24 hours apart. In the first and second sessions, respectively, placebo (D5W) or tariquidar (4mg/kg dose in D5W) 22 will be administered IV over 60 minutes. Ondansetron will be diluted in 50mL 0.9% normal saline, and tariquidar will be diluted in 250mL D5W.
Study: NCT04481763

Intervention type: DRUG
Group type: OTHER
Intervention: Camrelizumab
Description: Camrelizumab is 200 mg iv. administered every 2 weeks for 3 cycles with radiotherapy ( 50gy, 25 times for 5weeks)

Intervention type: RADIATION
Group type: OTHER
Intervention: radiotherapy
Description: radiotherapy
Study: NCT01712048

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Submucosal Injection EMR
Description: Selective saline injection is applied to the layer of tissue underneath the polyp in order to create a safety cushion for resection. EMR is then performed with a standard snare.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Underwater EMR
Description: Polypectomy is performed under full water emersion without the use of submucosal injection.
Study: NCT02771860

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: denosumab
Description: 60mg sc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: denosumab
Description: 60mg sc

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical syringe

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium/Vit D supplementation
Description: Daily dosage Calcium 1000mg / Vit D 880 IU

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium/Vit D supplementation
Description: Daily dosage Calcium 1000mg / Vit D 880 IU
Study: NCT01698268

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: TAP Block will be performed under ultrasound guidance via Sonosite device with an in-plane technique by the anesthesiologist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Infiltration
Description: Local infiltration of 0.5 cc/kg of 0.25% ropivacaine will be administered by the surgeon.
Study: NCT01058291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6500
Description: Twelve weeks subcutaneous injection of 1 to 6 mg for the OFF state

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KW-6500 Placebo
Description: Twelve weeks subcutaneous injection for the OFF state
Study: NCT00717795

Intervention type: BEHAVIORAL
Intervention: interview and physical activity
Description: For Arm 1 participants in the Physical Activity intervention condition will be assessed at baseline, and postintervention Follow-up (at 12 weeks post baseline).
Study: NCT04247542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibezapolstat
Description: Investigational antibacterial agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Active comparator